The US Food and Drug Administration (FDA) has approved an additional indication for the weight loss drug semaglutidemarketed as Wegovy (Novo Nordisk) to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight along with a reduced calorie diet and increased physical activity
10.1016/j.bbi.2020.03.026 286 LiuT.SunW.GuoS.ChenT.ZhuM.YuanZ.et al
Additional safety and quality information can be provided by your pharmacy
Long-term success requires combining medication with sustained dietary and lifestyle changes to prevent rebound
This rare condition affects only 2-10 out of every 100,000 people and is the second leading cause of blindness from optic nerve damage, following glaucoma
The situation for Ozempic generics is slightly different in Canada, as Novo Nordisks patent protection expired in January 2026, and Health Canada has already received multiple active applications from companies seeking to sell generic semaglutide